Although novel CT techniques, such as 3D-CT volumetry, appear more sensitive in response prediction, van Heijl notes in a 2011 study that tumour volume fluctuates paradoxically during the course of NAT and hence should not be relied upon to accurately reflect pathological response [18]. The gene discussed is BRD2; the disease is neoplasm.